A S Stein
Overview
Explore the profile of A S Stein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar B, Garcia M, Weng L, Jung X, Murakami J, Hu X, et al.
Leukemia
. 2017 Aug;
32(3):575-587.
PMID: 28816238
Little is known about how leukemia cells alter the bone marrow (BM) niche to facilitate their own growth and evade chemotherapy. Here, we provide evidence that acute myeloid leukemia (AML)...
2.
Topp M, Gockbuget N, Stein A
Lancet Oncol
. 2015 Apr;
16(4):e158.
PMID: 25846094
No abstract available.
3.
Vanderwalde A, Sun C, Laddaran L, Francisco L, Armenian S, Berano-Teh J, et al.
Leukemia
. 2012 Nov;
27(5):1139-45.
PMID: 23183426
The probability of survival is conventionally calculated from autologous hematopoietic cell transplantation (aHCT). Conditional survival takes into account the changing probability of survival with time survived, but this is not...
4.
Kirschbaum M, Synold T, Stein A, Tuscano J, Zain J, Popplewell L, et al.
Leukemia
. 2011 Jun;
25(10):1543-7.
PMID: 21625235
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose-escalation study of tipifarnib, an oral...
5.
Stein A, ODonnell M, Synold T, Dagis A, Tsirunyan A, Nademanee A, et al.
Bone Marrow Transplant
. 2010 Dec;
46(9):1256-62.
PMID: 21151180
Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and...
6.
Pullarkat V, Slovak M, Dagis A, Bedell V, Somlo G, Nakamura R, et al.
Ann Oncol
. 2009 Jul;
20(12):2000-6.
PMID: 19564171
Background: Although secondary acute leukemias and myelodysplasia are the known complications of adjuvant chemotherapy for breast cancer, the treatment outcome of these secondary malignancies is presently unclear. We examined the...
7.
Stein A, ODonnell M, Slovak M, Nademanee A, Dagis A, Schmidt G, et al.
Leukemia
. 2000 Jul;
14(7):1191-6.
PMID: 10914541
Cytogenetic abnormalities are used to define prognostic subgroups of acute myelogenous leukemia (AML) with respect to achieving complete remission (CR) and remaining disease free. These prognostic groups for obtaining CR...
8.
Snyder D, Nademanee A, ODonnell M, Parker P, Stein A, Margolin K, et al.
Leukemia
. 1999 Dec;
13(12):2053-8.
PMID: 10602428
Between 1984 and 1997, 23 consecutive patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in first complete remission were treated with allogeneic bone marrow transplants from HLA-matched siblings. All patients but...
9.
ROSS M, Schmidt G, Niland J, Amylon M, Dagis A, Long G, et al.
Biol Blood Marrow Transplant
. 1999 Oct;
5(5):285-91.
PMID: 10534058
Graft-vs.-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation (BMT). For patients alive at day 100 after BMT, the presence or absence of chronic GVHD...
10.
Smith E, Sniecinski I, Dagis A, Parker P, Snyder D, Stein A, et al.
Biol Blood Marrow Transplant
. 1998 Aug;
4(1):27-37.
PMID: 9701389
Extracorporeal photochemotherapy (EP) is a therapeutic approach to the treatment of drug-resistant graft-vs.-host disease (GVHD) that uses the known immunosuppressive and immunomodulatory effects of ultraviolet light. In 1990, we initiated...